FDA clears United Therapeutics to begin phase‑2 SUMMIT trial of treprostinil SMI in PH‑COPD
United Therapeutics received FDA clearance on Oct. 19, 2026 to start the SUMMIT phase‑2 study of its inhaled treprostinil soft‑mist inhaler for pulmonary hypertension associated with chronic obstructive pulmonary disease (PH‑COPD). The 16‑week, double‑blind trial will enroll approximately 40 patients to evaluate safety, tolerability and secondary efficacy endpoints. The company said a successful outcome would lead to a phase‑3 registration study slated for 2028.
Why it matters
The clearance allows United Therapeutics to advance a new indication that could address an unmet need in a patient population estimated at 400,000‑800,000 in the U.S., potentially expanding the company’s market size if the drug gains approval.
Key facts
- 1The FDA granted clearance under United Therapeutics’ IND to proceed with the SUMMIT trial on Oct. 19, 2026. rttnews.com
- 2The SUMMIT study is a phase‑2, 16‑week, double‑blind trial that will enroll approximately 40 patients with PH‑COPD. gurufocus.com
- 3If the phase‑2 study is successful, United Therapeutics plans to begin a phase‑3 registration study for treprostinil SMI in PH‑COPD in 2028. rttnews.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.